Ernexa Therapeutics Inc. (ERNA) stock
ERNANasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as ERNAW
$1.93−0.08 (-3.98%)
Close on Nov 11, 2026Market cap $3.15MP/E –Yield –
Ernexa Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Ernexa Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $7.25M, up 56.4% year over year. For fiscal 2025 it was $4.16M, down 9.7% from the year before. The highest annual figure on record is $12.71M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.16M | -9.7% |
| FY2024 | Dec 31, 2024 | $4.60M | -22.2% |
| FY2023 | Dec 31, 2023 | $5.92M | -43.0% |
| FY2022 | Dec 31, 2022 | $10.39M | -18.2% |
| FY2021 | Dec 31, 2021 | $12.71M | +221.6% |
| FY2020 | Dec 31, 2020 | $3.95M | +15096.2% |
| FY2019 | Dec 31, 2019 | $26.00K | -63.9% |
| FY2018 | Dec 31, 2018 | $72.00K | -48.2% |
| FY2017 | Dec 31, 2017 | $139.00K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.87M | +80.8% |
| Q2 FY2026 | Jun 30, 2026 | $2.79M | +145.8% |
| Q1 FY2026 | Mar 31, 2026 | $1.92M | +46.3% |
| Q4 FY2025 | Dec 31, 2025 | $676.00K | -41.6% |
| Q3 FY2025 | Sep 30, 2025 | $1.04M | +3.4% |
| Q2 FY2025 | Jun 30, 2025 | $1.14M | +15.1% |
| Q1 FY2025 | Mar 31, 2025 | $1.31M | -10.2% |
| Q4 FY2024 | Dec 31, 2024 | $1.16M | -14.9% |
| Q3 FY2024 | Sep 30, 2024 | $1.00M | -27.8% |
| Q2 FY2024 | Jun 30, 2024 | $987.00K | -34.2% |
| Q1 FY2024 | Mar 31, 2024 | $1.46M | -12.9% |
| Q4 FY2023 | Dec 31, 2023 | $1.36M | -30.7% |
| Q3 FY2023 | Sep 30, 2023 | $1.39M | -72.1% |
| Q2 FY2023 | Jun 30, 2023 | $1.50M | -11.0% |
| Q1 FY2023 | Mar 31, 2023 | $1.67M | -6.1% |
| Q4 FY2022 | Dec 31, 2022 | $1.96M | -53.8% |
| Q3 FY2022 | Sep 30, 2022 | $4.96M | +232.9% |
| Q2 FY2022 | Jun 30, 2022 | $1.69M | -69.0% |
| Q1 FY2022 | Mar 31, 2022 | $1.78M | +16.2% |
| Q4 FY2021 | Dec 31, 2021 | $4.25M | +157.3% |
| Q3 FY2021 | Sep 30, 2021 | $1.49M | +61.4% |
| Q2 FY2021 | Jun 30, 2021 | $5.43M | – |
| Q1 FY2021 | Mar 31, 2021 | $1.53M | – |
| Q4 FY2020 | Dec 31, 2020 | $1.65M | – |
| Q3 FY2020 | Sep 30, 2020 | $923.53K | – |
See a number that looks wrong?